Abstract
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous malignancy and the second most lethal cancer in men amongst the United States. Localized tumors are effectively treated via radical prostatectomy and/or radiation therapy, however disseminated disease contributes greatly to patient morbidity. At present, therapeutic intervention for metastatic disease capitalizes on the addiction of these tumors to the androgen receptor (AR). The AR signaling axis regulates cell growth, proliferation, and migration of cancer cells, which makes understanding the contribution of AR toward these signaling pathways integral for PCa eradication. Several key signaling molecules are currently known to be controlled by AR and promote migration and invasion in castrate-resistant PCa (CRPC). This concept will be explored with regard to the interplay between AR and chemokine receptors, chromosomal fusions, oncogenes, and microRNAs. Additionally, current and preclinical AR-directed therapeutics used for treatment of metastatic PCa, which impinge on these pathways, and overall AR activity, will be discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- Abiraterone:
-
Abiraterone acetate
- ADT:
-
Androgen deprivation therapy
- AR:
-
Androgen receptor
- BC:
-
Bicalutamide (Casodex)
- CDKS:
-
Cyclin-dependent kinases
- CML:
-
Chronic myelogenous leukemia
- CRPC:
-
Castration resistant prostate cancer
- CTCs:
-
Circulating tumor cells
- DHT:
-
5α-dihydrotestosterone
- E-Box:
-
Enhancer box
- ETS:
-
Erythroblast transformation specific transcription factor
- FAK:
-
Focal adhesion kinase
- FISH:
-
Florescence in-situ hybridization
- Flutamide:
-
Hydroxyflutamide
- GnRH:
-
Gonadotropin releasing hormone
- HATs:
-
Histone acetyltransferases
- HSPs:
-
Heat shock proteins
- IHC:
-
Immunohistochemistry
- KLF5:
-
Kruppel-like-factor 5
- LBD:
-
Ligand binding domain
- MMPs:
-
Matrix metalloproteinases
- miRNA:
-
MicroRNA
- MYC:
-
c-Myc
- NCoR1:
-
Nuclear Co-Repressor 1
- PIN:
-
Prostatic intraepithelial neoplasia
- PcG:
-
Polycomb-group
- PCa:
-
Prostate cancer
- PSA:
-
Prostate specific antigen
- SDF-1:
-
Stromal cell-derived factor 1
- SFK:
-
Macrophage inflammatory protein
- SRC:
-
Steroid receptor coactivator
- TRAMP:
-
Transgenic adenocarcinoma of the mouse prostate
- TMPRSS2:
-
Transmembrane protease serine 2
- VCaP:
-
Vertebral-Cancer of the Prostate
References
Jemal A et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96
Klein EA et al (2009) Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? Urol Oncol 27(1):67–71
Klotz L (2006) Combined androgen blockade: an update. Urol Clin North Am 33(2):161–166, v–vi
Knudsen KE, Scher HI (2009) Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 15(15):4792–4798
Loblaw DA et al (2007) Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25(12):1596–1605
Yuan X, Balk SP (2009) Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 27(1):36–41
Lawton CA et al (2001) Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49(4):937–946
Bolla M et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360(9327):103–106
Bubendorf L et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31(5):578–583
Cunha GR et al (2004) Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 92(4):221–236
Penning TM et al (2008) Pre-receptor regulation of the androgen receptor. Mol Cell Endocrinol 281(1–2):1–8
Centenera MM et al (2008) The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol 22(11):2373–2382
Chmelar R et al (2007) Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 120(4):719–733
Agoulnik IU, Weigel NL (2008) Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol 617:245–255
Balk SP, Knudsen KE (2008) AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6:e001
Beekman KW, Hussain M (2008) Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient. Urol Oncol 26(4):415–419
Ryan CJ et al (2006) Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology 68(4):834–839
Knudsen KE, Penning TM (2010) Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 21(5):315–324
Chen Y, Sawyers CL, Scher HI (2008) Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8(4):440–448
van Poppel H, Nilsson S (2008) Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 71(6):1001–1006
Oefelein MG (1998) Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 160(5):1685–1688
Linja MJ et al (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61(9):3550–3555
Latil A et al (2001) Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61(5):1919–1926
Ford OH 3rd et al (2003) Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 170(5):1817–1821
Edwards J et al (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89(3):552–556
Sharma A et al (2010) The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 120(12):4478–4492
Donovan MJ et al (2010) Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 105(4):462–467
Taplin ME (2007) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 4(4):236–244
Brooke GN, Bevan CL (2009) The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10(1):18–25
Middleman MN, Lush RM, Figg WD (1996) The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate. Pharmacotherapy 16(3):376–381
Dehm SM et al (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68(13):5469–5477
Hu R et al (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69(1):16–22
Guo Z et al (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69(6):2305–2313
Jenster G et al (1995) Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 270(13):7341–7346
Xu J, Wu RC, O’Malley BW (2009) Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 9(9):615–630
Gregory CW et al (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61(11):4315–4319
Agoulnik IU et al (2005) Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 65(17):7959–7967
Agoulnik IU, Weigel NL (2009) Coactivator selective regulation of androgen receptor activity. Steroids 74(8):669–674
Comuzzi B et al (2003) The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol 162(1):233–241
Shang Y, Myers M, Brown M (2002) Formation of the androgen receptor transcription complex. Mol Cell 9(3):601–610
Burd CJ, Morey LM, Knudsen KE (2006) Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer 13(4):979–994
Knudsen KE (2006) The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Div 1:15
Comstock CE et al (2009) Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res 15(17):5338–5349
Montgomery RB et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68(11):4447–4454
Wang Q et al (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138(2):245–256
Wang Q et al (2007) A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27(3):380–392
Sobel RE, Sadar MD (2005) Cell lines used in prostate cancer research: a compendium of old and new lines–part 1. J Urol 173(2):342–359
Furusato B et al (2010) CXCR4 and cancer. Pathol Int 60(7):497–505
Sun X et al (2010) CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 29(4):709–722
Vindrieux D, Escobar P, Lazennec G (2009) Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 16(3):663–673
Sun YX et al (2003) Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89(3):462–473
Fernandis AZ et al (2004) Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 23(1):157–167
Prasad A et al (2004) Slit protein-mediated inhibition of CXCR4-induced chemotactic and chemoinvasive signaling pathways in breast cancer cells. J Biol Chem 279(10):9115–9124
Kukreja P et al (2005) Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res 65(21):9891–9898
Wang JF, Park IW, Groopman JE (2000) Stromal cell-derived factor-1alpha stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: roles of phosphoinositide-3 kinase and protein kinase C. Blood 95(8):2505–2513
Mitra SK, Schlaepfer DD (2006) Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18(5):516–523
McGrath KE et al (1999) Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Dev Biol 213(2):442–456
Sun YX et al (2005) Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 20(2):318–329
Frigo DE et al (2009) Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. Mol Endocrinol 23(9):1385–1396
Mochizuki H et al (2004) Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Biochem Biophys Res Commun 320(3):656–663
Kazmin D et al (2006) Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. Mol Endocrinol 20(6):1201–1217
Jamieson WL et al (2008) CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res 68(6):1715–1722
Tomlins SA et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644–648
Mehra R et al (2008) Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68(10):3584–3590
Iljin K et al (2006) TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66(21):10242–10246
Mani RS et al (2009) Induced chromosomal proximity and gene fusions in prostate cancer. Science 326(5957):1230
Lin C et al (2009) Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139(6):1069–1083
Mertz KD et al (2007) Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 9(3):200–206
Bastus CN et al (2010) Androgen-induced TMPRSS2:ERG fusion in non-malignant prostate epithelial cells. Cancer Res 70(23):9544–9548
Hendriksen PJ et al (2006) Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66(10):5012–5020
Tomlins SA et al (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10(2):177–188
Klezovitch O et al (2008) A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105(6):2105–2110
Cai J et al (2010) Androgens induce functional CXCR4 through ERG factor expression in TMPRSS2-ERG fusion-positive prostate cancer cells. Transl Oncol 3(3):195–203
Zong Y et al (2009) ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci USA 106(30):12465–12470
Wang J et al (2006) Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66(17):8347–8351
Wang J et al (2008) Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 68(20):8516–8524
Mehra R et al (2007) Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20(5):538–544
Mosquera JM et al (2008) Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 14(11): 3380–3385
Selbach M et al (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455(7209):58–63
Dastugue N et al (2002) Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood 100(2):618–626
Sorensen PH et al (1994) A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 6(2):146–151
Demichelis F et al (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31):4596–4599
Laxman B et al (2008) A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68(3):645–649
Laxman B et al (2006) Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8(10):885–888
Rostad K et al (2009) TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 117(8):575–582
Coppola V, De Maria R, Bonci D (2010) MicroRNAs and prostate cancer. Endocr Relat Cancer 17(1):F1–F17
Garzon R, Marcucci G, Croce CM (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9(10):775–789
Lu J et al (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043):834–838
Calin GA et al (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101(9):2999–3004
Volinia S et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7):2257–2261
Narayanan R et al (2010) MicroRNAs are mediators of androgen action in prostate and muscle. PLoS One 5(10):e13637
Ambs S et al (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68(15):6162–6170
Ribas J et al (2009) miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69(18):7165–7169
Shi XB et al (2007) An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA 104(50):19983–19988
Varambally S et al (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322(5908):1695–1699
Wang HJ et al (2010) MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer 46(12):2295–2303
Cao P et al (2010) MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 9:108
Schulz WA, Hatina J (2006) Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med 10(1):100–125
Lawrie CH (2007) MicroRNA expression in lymphoma. Expert Opin Biol Ther 7(9):1363–1374
Navarro A et al (2008) MicroRNA expression profiling in classic Hodgkin lymphoma. Blood 111(5):2825–2832
Wang G et al (2008) Transcription factor and microRNA regulation in androgen-dependent and -independent prostate cancer cells. BMC Genomics 9(Suppl 2):S22
Li T et al (2009) MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 383(3):280–285
Lin SL et al (2008) Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14(3):417–424
Wang L et al (2009) Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 69(24):9490–9497
Gallucci M et al (2006) Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma. Cancer Lett 237(1):76–82
Gallucci M et al (2009) Genetic profile identification in clinically localized prostate carcinoma. Urol Oncol 27(5):502–508
Leversha MA et al (2009) Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 15(6):2091–2097
Jenkins RB et al (1997) Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57(3):524–531
Sato K et al (1999) Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 91(18):1574–1580
Iwata T et al (2010) MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One 5(2):e9427
Ellwood-Yen K et al (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4(3):223–238
Watson PA et al (2005) Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 65(24):11565–11571
Visakorpi T et al (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9(4):401–406
Chuan YC et al (2010) Ezrin mediates c-Myc actions in prostate cancer cell invasion. Oncogene 29(10):1531–1542
Silva IS et al (2001) Androgen-induced cell growth and c-myc expression in human non-transformed epithelial prostatic cells in primary culture. Endocr Res 27(1–2):153–169
Sun C et al (2008) TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27(40):5348–5353
Grad JM et al (1999) Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Mol Endocrinol 13(11):1896–1911
Khanna C et al (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10(2):182–186
Yu Y et al (2004) Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 10(2):175–181
Chuan YC et al (2006) Androgen induction of prostate cancer cell invasion is mediated by ezrin. J Biol Chem 281(40):29938–29948
Nupponen NN et al (1998) Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 153(1):141–148
de Bono JS et al (2008) Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 14(20):6663–6673
Kaltz-Wittmer C et al (2000) FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 80(9):1455–1464
Gurel B et al (2008) Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 21(9):1156–1167
Hawksworth D et al (2010) Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 13(4):311–315
Wolfer A et al (2010) MYC regulation of a “poor-prognosis” metastatic cancer cell state. Proc Natl Acad Sci USA 107(8):3698–3703
Martin GS (1970) Rous sarcoma virus: a function required for the maintenance of the transformed state. Nature 227(5262):1021–1023
Saad F, Lipton A (2010) SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 36(2):177–184
Guo Z et al (2006) Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10(4):309–319
Kraus S et al (2006) Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res 66(22):11047–11054
Asim M et al (2008) Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene 27(25):3596–3604
Gingrich JR et al (1997) Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57(21):4687–4691
Tatarov O et al (2009) SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 15(10):3540–3549
Araujo J, Logothetis C (2010) Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev 36(6):492–500
Park SI et al (2008) Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68(9):3323–3333
Labrie F et al (2005) Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 26(3):361–379
Shepard DR, Raghavan D (2010) Innovations in the systemic therapy of prostate cancer. Nat Rev Clin Oncol 7(1):13–21
Haidar S et al (2003) Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol 84(5):555–562
Attard G et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26(28):4563–4571
Reid AH et al (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28(9):1489–1495
Tran C et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787–790
Culig Z et al (1999) Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81(2):242–251
Scher HI et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375(9724):1437–1446
Handratta VD et al (2005) Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 48(8):2972–2984
Vasaitis T et al (2008) Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 7(8):2348–2357
Andersen RJ et al (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17(6):535–546
Shen R et al (2000) Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 141(5):1699–1704
Xu K et al (2009) Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 15(4):270–282
Acknowledgements
We would like to thank all the members of the K. Knudsen lab, especially M. Schiewer, for insightful feedback and critical reading of this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Schrecengost, R.S., Augello, M.A., Knudsen, K.E. (2011). Androgen Receptor Regulation of Prostate Cancer Progression and Metastasis. In: Fatatis, A. (eds) Signaling Pathways and Molecular Mediators in Metastasis. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2558-4_12
Download citation
DOI: https://doi.org/10.1007/978-94-007-2558-4_12
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-2557-7
Online ISBN: 978-94-007-2558-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)